Generative AI can enhance pharmaceutical innovation – but are you ready for it?

Sponsored content By SAS

Generative AI has been the buzz of the life sciences industry over the past 18 months. In fact, it’s been the buzz of nearly every industry all around the world.

Both artificial intelligence (AI) and generative AI (GenAI) have the potential to revolutionize drug development, optimize research processes, and ultimately speed up time to market to deliver therapies to patients more effectively. At the same time, these technologies also pose limitations, and have to be handled with the utmost rigor and compliance to be effective.

There’s no doubt that GenAI can enhance innovation in pharma – the question, however, is whether organizations are ready to embrace the technology in a way that makes sense for...

Today's Sponsors

Today's Sponsor